Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 3 AST profile per bacteria (Enterobacterales)

From: French national epidemiology of bacterial superinfections in ventilator-associated pneumonia in patients infected with COVID-19: the COVAP study

Enterobacterales

Whole-group

Escherichia coli

Klebsiella pneumoniae/sp.

Enterobacter cloacae/sp.

Serratia marcescens

COVID + (n; %)

COVID-(n; %)

p-value

COVID + (n; %)

COVID-(n; %)

p-value

COVID + (n; %)

COVID-(n; %)

p-value

COVID + (n; %)

COVID-(n; %)

p-value

COVID + (n; %)

COVID-(n; %)

p-value

β-lactam (n; % of evaluated in the respective group)

–*

–*

–*

–

–

 < 0.05

  

 < 0.05 < 0.05

–

–

–

  

–

WT

–*

–*

–*

27 (39.1)

6 (42.9)

–

29 (22.3)/49 (37.7)

9 (90.0)/12 (57.1)

 < 0.05/–a

24 (47.1)/25 (46.3)

4 (40)/6 (50)

–/–

–

 

–

Cephalosporinase

–*

–*

–*

6 (8.7)

4 (28.6)

 < 0.05

3 (2.3)/34 (26.2)

0 (0)/4 (19)

–/–

–

–

–

31 (93.9)

8 (88.9)

–

HC

–*

–*

–*

3 (4.3)

0 (0)

–

4 (3.1)/25 (19.2)

1 (10.0)/5 (23.8)

–/–

14 (27.4)/14 (25.9)

6 (60)/6 (50)

 < 0.05/–

2 (6.1)

1 (11.1)

–

e-ESBL

–*

–*

–*

15 (21.7)

1 (7.1)

–

18 (13.8)/19 (14.6)

0 (0)/0 (0)

–/–a

9 (17.6)/9 (16.7)

0 (0)/0 (0)

–/–

–

–

–

HP

–*

–*

–*

18 (26.1)

3 (21.4)

–

–

–

–

–

–

–/–

–

–

–

CPE

–*

–*

–*

–

–

–

1 (0.8)/3 (2.3)

0 (0)/0 (0)

–/–

4 (7.8)/4 (7.4)

0 (0)/0 (0)

–/–

–

–

–

Aminoglycosides-resistant (n; % of evaluated in the respective group)

72 (13.9)

14 (20.0)

 < 0.05

8 (11.6)

2 (14.3)

–

20 (0)/23 (17.6)

1 (10.0)/1 (4.8)

–/–

10 (20.8)/10 (19.6)

1 (11.1)/1 (9.0)

–/–

13 (44.8)

1 (12.5)

 < 0.05

Quinolone-resistant (n; % of evaluated in the respective group)

60 (17.8)

7 (9.7)

–

18 (26.9)

2 (14.2)

–

18 (32.7)/22 (16.8)

1 (10)/1 (4.8)

–/–

12 (23.5)/12 (22.6)

3 (30)/3 (27.3)

–/–

0 (0)

0 (0)

–

Fosfomycin-resistant (n; % of evaluated in the respective group)

59 (29.8)

6 (15.0)

–a

2 (5.7)

0 (0)

–

17 (48.6)/40 (47.1)

2 (40)/3 (25)

–/–

6 (22.2)/6 (20)

1 (14.2)/1 (12.5)

–/–

–

–

–

Cotrimoxazole-resistant (n; % of evaluated in the respective group)

67 (18.5)

4 (6.1)

 < 0.05

19 (28.4)

0 (0)

–

21 (39.6)/23 (18.4)

0 (0)/0 (0)

 < 0.05/–

13 (26.0)/13 (24.5)

2 (20)/2 (18.2)

–/–

0 (0)

0 (0)

–

  1. WT wild-type, HC hyper-expressed cephalosporinase, e-ESBL Extended-spectrum beta-lactamase producing enterobacterales, Hyper-expressed penicillinase, CPE Carbapenemase-producing enterobacterales, *: non evaluated
  2. aStatistical tendency (p < 0.10)
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us